首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1881254

藥物遞送合作與許可協議（2019-2025）

Drug Delivery Collaboration and Licensing Deals 2019-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

"藥物遞送合作與許可協議" 全面深入地分析了全球領先的生物製藥公司簽署的藥物遞送協議，並提供前所未有的資訊取得管道。

這份經過全面修訂和更新的報告詳細介紹了2019年至2025年間的藥物遞送協議。

本報告深入分析了企業簽署藥物遞送協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，逐步推進到成果的商業化。

本報告涵蓋合作研發、研究和授權等內容。

本報告包含自2019年以來公佈的1246項藥物遞送協議的完整列表，其中包括可用的財務條款以及各方披露的實際藥物遞送合作協議的在線記錄鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了藥物遞送領域的交易活動。

第一章概述了本報告。

第二章概述了自 2019 年以來的藥物遞送交易活動。

第三章概述了自 2019 年以來主要的藥物遞送交易，並依交易總額列出。

第四章提供了藥物遞送領域交易活動最活躍的前 25 家公司的完整列表，並附有簡要概述，以及藥物遞送交易和公開合約文件的完整列表。

第五章對自 2019 年 1 月以來已完成或已宣布的、且有公開合約文件的藥物遞送交易進行了全面深入的審查。

第六章對自2019年1月以來已達成或宣布的藥物遞送領域合作協議進行了全面深入的回顧。本章以具體的藥物遞送技術類型進行組織。

報告還包含大量表格和圖表，顯示了自2019年以來藥物遞送技術交易的趨勢和動態。

此外，我們還提供了一個全面的交易目錄，依公司名稱（A-Z）、交易類型和治療靶點進行分類。每個交易標題都透過網路連結指向線上交易記錄和可用的協議文件，方便用戶根據需要輕鬆存取每個協議文件。

主要優勢

"藥物遞送技術合作與授權協議" 報告提供讀者以下主要優勢：

了解 2019 年及以後的交易趨勢
瀏覽藥物遞送合作與授權協議
基準分析 - 確定交易市場價值
財務條款 - 預付款、里程碑付款、特許權使用費
依公司（A-Z）、協議類型和治療領域分類的合約目錄
以價值排名的主要交易
最活躍的交易撮合者
確定每筆交易的資產和條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
節省數百小時的研究時間

範圍

"藥物 "藥物遞送合作與授權協議" 旨在幫助讀者深入了解全球主要生物製藥公司在藥物遞送技術領域的合作趨勢和合約結構。

"藥物遞送合作研究與授權協議" 內容：

生物製藥產業藥物遞送交易趨勢
製藥和生物技術公司藥物遞送交易記錄目錄
以價值排名的主要藥物遞送交易
最活躍的藥物遞送許可協議公司
"藥物遞送合作研究與許可協議" 提供全面的交易記錄存取權限，包括可用的合約文件。

分析合約內容有助於對以下方面進行盡職調查：

合約中具體授予或選擇哪些權利？
合約實際上賦予合作夥伴哪些權利？
授予了哪些排他性權利？
交易的付款結構是怎麼樣的？
銷售和付款如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
知識產權（IPR）如何處理與歸屬？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和資訊揭露？
如何解決爭議？
在什麼情況下可以終止合約？
如果所有權發生變更，會發生什麼事？
如何約定轉讓許可和分包條款？
貴公司要求哪些標準條款？
哪些標準條款會因交易對手和交易類型而異？
貴公司必須受哪個司法管轄區管轄？

引言
歷年藥物遞送交易
最活躍的藥物遞送交易參與者
依交易類型劃分的藥物遞送交易
依治療領域劃分的藥物遞送交易
依行業劃分的藥物遞送交易
藥物遞送交易條款
- 藥物遞送交易總額
- 藥物遞送協議中的預付款
- 藥物遞送協議中的里程碑付款
- 藥物遞送特許權使用費率

第三章 - 主要藥物遞送交易

引言
以價值排名的頂級藥物輸送交易

第四章 - 最活躍的藥物傳輸交易商

引言
最活躍的藥物傳輸交易商
最活躍的藥物輸送交易公司簡介

第五章 - 藥物輸送合約交易目錄

引言
藥物輸送合約交易目錄

第六章 - 依技術類型劃分的藥物輸送交易

交易目錄
依公司劃分的藥物輸送交易目錄 (AZ)
以交易類型劃分的藥物輸送交易目錄
依治療領域劃分的藥物傳輸交易目錄
交易類型定義
關於研究公司
當前合作夥伴關係
當前合約
目前合作夥伴的當前報告標題

簡介目錄

Product Code: CP2102

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1246 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse drug delivery collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

Trends in drug delivery dealmaking in the biopharma industry
Directory of drug delivery deal records covering pharmaceutical and biotechnology
The leading drug delivery deals by value
Most active drug delivery licensing dealmakers
Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery deals over the years
2.3. Most active drug delivery dealmakers
2.4. Drug delivery deals by deal type
2.5. Drug delivery deals by therapy area
2.6. Drug delivery deals by industry sector
2.7. Deal terms for drug delivery deals
- 2.7.1 Drug delivery deals headline values
- 2.7.2 Drug delivery deal upfront payments
- 2.7.3 Drug delivery deal milestone payments
- 2.7.4 Drug delivery royalty rates